7733.T Olympus Corporation Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
18:33
Feb 17
Feb 17
Olympus undervalued; FDA/restructuring temporary, 32% margin of safety
The author argues Olympus (7733.T) is undervalued after FDA ship-holds and restructuring cut guidance; normalizing owner earnings for the wind-down of Project Elevate, ship-hold recovery and run-rate savings yields ¥107B and, at a conservative 24x multiple, intrinsic value of ¥2,319/share versus ¥1,568, a 32% margin of safety. Catalysts include resolution of FDA ship-holds (management expects most gross margin pressure resolved in Q4), completion of Project Elevate by March 2026, restructuring savings, and potential OLYSENSE AI software adoption by FY31. The main stated risk is that management may be too optimistic on ship-hold recovery and competitors may have taken some market share due to regulatory troubles.
HIGH
About 7733.T Investor Commentary
Across the available history and selected sources, Buzzberg tracks 7733.T (Olympus Corporation) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Far_Preference_2065.